

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Jorg Sturzebecher et al.	Confirmation No.:	4120
Serial No.:	10/540,958	Art Unit:	1611
Filed:	January 3, 2006	Examiner:	M. Sznaidman
Customer No.:	21559		
Title:	ACYLATED 4-AMIDINO AND 4-GUANIDINO BENZYLAMINES FOR INHIBITION OF PLASMA KALLIKREIN		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REPLY TO RESTRICTION REQUIREMENT

As an initial matter, Applicants thank the Examiner for the telephonic communication of August 14, 2008, clarifying that claim 76 should be included in Group I of the Restriction Requirement that was mailed in connection with the above-captioned application on July 18, 2008. In reply to the Restriction Requirement, Applicants elect the invention of Group I, claims 46-74, 76, and 88-89, and the species of compound 53, (Table 3, page 53), plasma kallikrein as the serine protease, and antithrombotic agent, e.g., for preventing blood coagulation at synthetic surfaces, for the disease or condition. Applicants have elected the disease or condition of claim 70, rather than one specified in claim 72 or 73. The elected species read on claims 46-48, 59, 63-66, 70, and 74. The election is made without traverse.

If there are any charges or any credits, please apply them to Deposit Account No.

03-2095.

Respectfully submitted,

Date: August 18, 2008

Susan M. Michaud
Karen L. Elbing, Ph.D. Susan M. Michaud
Reg. No. 35,238 Reg. No. 42,885

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045